Laurus Labs

LAURUSLABS.NS

Hyderabad, India· Est. 2005

lauruslabs.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

LAURUSLABS.NS · Stock Price

INR 1,206.50+617.70 (+104.91%)

Market Cap: $7.0B

Historical price data

Market Cap: $7.0BPatents: 20Founded: 2005Employees: 4000-6000HQ: Hyderabad, India

Sector Ranking#19 in Small Molecule Drugs #12 in Biologics / Biosimilars

Overview

Laurus Labs' mission is to be a leading global provider of integrated pharmaceutical development and manufacturing solutions, guided by core values of knowledge, innovation, and integrity. The company has achieved significant growth since its 2016 IPO, transitioning from an API specialist to a diversified player with strongholds in HIV therapeutics, complex generics, and a fast-growing CDMO segment. Its strategy hinges on vertical integration, expansion into high-margin non-ARV segments, and building next-generation capabilities in biotechnology to drive future growth.

HIV/AIDSOncologyCardiovascularDiabetesGastroenterology

Technology Platform

Integrated platform for advanced chemical synthesis, process development, and scalable manufacturing of APIs and FDFs, with emerging capabilities in biopharmaceuticals including cell and gene therapy manufacturing.

Funding History

Total raised:$250M

PIPE$100MGoldman SachsJul 15, 2020

IPO$150MUndisclosedDec 21, 2016

FDA Approved Drugs

EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATEANDAMar 4, 2026

FLUCYTOSINEANDAJul 23, 2025

SACUBITRIL AND VALSARTANANDAMay 28, 2024

Opportunities

Significant growth is expected from the global outsourcing trend in pharmaceuticals (CDMO), expansion into complex non-ARV generics, and the long-term potential of its early investment in cell and gene therapy manufacturing capacity.

The 'China+1' supply chain diversification also benefits its established regulatory platform.

Risk Factors

Key risks include regulatory compliance failures at major facilities, pricing pressure and customer concentration in the ARV segment, execution challenges in scaling new business segments, and the high capital intensity and technical risk associated with the biotechnology foray.

Competitive Landscape

Laurus competes with large Indian pharma firms (Sun Pharma, Dr. Reddy's) in formulations, specialized API manufacturers, and CDMOs like Divi's Labs and Syngene. Its vertical integration, strong regulatory track record, and early move into biologics CDMO provide distinct competitive advantages in a crowded market.